Ryosuke Harada
Chugai Pharmaceutical Co., Ltd. (Japan) · 5 works · 811 citations · h-index 4
Top works
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- Association Between Baseline Pulmonary Status and Interstitial Lung Disease in Patients With Non–Small-Cell Lung Cancer Treated With Erlotinib—A Cohort Study
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.
- Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study
- [Anemia in patients on continuous ambulatory peritoneal dialysis (CAPD)].